AstraZeneca, an international biopharmaceutical company, and SKOLKOVO Foundation announced the launch of a joint acceleration program for projects in the area of oncology, cardiovascular, metabolic, kidney, respiratory, and autoimmune diseases.
The scientific partners of acceleration program include National Research Nuclear University MEPhI and Siberian State Medical University.
The goal of Startup Challenge 2018 is to find promising ideas and innovative solutions. Project participants will compete in two categories, including medicinal/biomedical cell products and test systems, hardware solutions and devices for drug delivery.
Irina Panarina, General Director of AstraZeneca Russia & Eurasia, said, “The development of pharmaceutical industry and search for innovative solutions to combat severe diseases represent a key priority for AstraZeneca. As part of our strategy “To be in Russia for Russia,” we pay great attention to the development of research potential. The launch of acceleration program is an important step in this direction, and we are confident that this project will allow to identify promising ideas for more effective diagnosis and treatment of diseases. This year, AstraZeneca celebrates 25th anniversary of its presence on the Russian market. Over this period, we introduced here more than 40 drugs that help patients lead longer and better lives. We see our mission in becoming a leading innovative partner to address the problems in the area of health care.”